– Sepsis remains the primary cause of death from infection, affecting 26 million people, and resulting in an estimated 5.3 million deaths worldwide each year
– Access PCT strengthens industry’s most extensive portfolio of in-vitro diagnostic testing for sepsis identification and management
– Rapid access to results in approximately 20 minutes
June, 11 2019 – Beckman Coulter – the global leader in clinical diagnostics, today announced the launch of Access PCT assay, the latest addition to its extensive menu for the Access Family of Immunoassay Systems. The state-of-the-art sensitivity and low-end precision of Access PCT assay combined with short incubation time, helps physicians in the risk assessment of critically ill patients in danger of progression to severe sepsis or septic shock, with test results available in under 20 minutes.
“Sepsis is a life-threatening systemic inflammatory response to infection. Despite advances in modern medicine, it remains the primary cause of death from infection, affecting 26 million people, and resulting in an estimated 5.3 million deaths worldwide each year,” said Jeannine Holden, M.D., chief medical officer at Beckman Coulter. “Procalcitonin levels in the blood have been found to correlate with the severity of bacterial infections and also with the probability of a positive blood culture, making it a clinically useful marker in the assessment of patients with possible sepsis or septic shock. The ability to rapidly diagnose suspected sepsis patients and determine appropriate care and treatment is critical, as earlier administration of antibiotics is highly correlated with increased patient survival.”
The launch of Access PCT follows the recent release of the Early Sepsis Indicator, a unique haematological marker available on Beckman Coulter’s DxH900 Hematology Analyzer as a part of the routine CBC with differential analysis.
“Our partners count on Beckman Coulter to provide a broad menu of solutions that matter in the treatment of the most prevalent and costly health conditions. We are proud to offer the industry’s most extensive portfolio of in-vitro diagnostic testing for sepsis identification and management across multiple disciplines, including clinical chemistry, immunoassay,
microbiology, urinalysis, and haematology, said Puneet Sarin, senior vice president and general manager for Beckman Coulter’s chemistry and immunoassay business. “Access PCT is a key component in the fight against sepsis and a testament to our ongoing investment in developing the tools physicians need to enhance patient care by enabling them to know sooner and act faster. In the fight against sepsis, every minute counts.”
Access PCT enables healthcare providers to integrate procalcitonin testing analysis into their routine sepsis workups on core laboratory analyzers, as a primary or reflex test programmed through Beckman Coulter’s REMISOL Advance middleware. Such integration simplifies laboratory workflow and optimizes institutional sepsis management protocols while reducing the operation expense of maintaining costly dedicated instrumentation.
The new Access PCT assay recently received CE mark certification and is available for use on the Access Family of Immunoassay Systems including the Access 2, UniCel DxI 600 and UniCel DxI 800.
About Beckman Coulter Diagnostics:
Beckman Coulter Diagnostics helps healthcare and laboratory professionals provide better patient care by delivering accurate diagnostic information they need, when they need it. With a rich 80-year history, Beckman Coulter is a strong partner for healthcare organizations. Our scalable instruments, comprehensive diagnostic tests, and business management services are trusted by hospitals, laboratories and other critical care settings around the world. We share in our customers’ mission toward continuous improvement and quality patient care because we believe when efficiency and clinical outcomes are improved, patients benefit and we can move healthcare forward for every person.
This Press Release has been sponsored by Beckman Coulter
Digital Health Buzz! aims to be the destination of choice when it comes to what’s happening in the digital health world. We are not about news and views, but informative articles and thoughts to apply in your business.